Advertisement
TOVX vs TVRD
Which Stock Would AI Choose? Theriva Biologics (TOVX) vs. Tvardi Therapeutics (TVRD) Stock Comparison
Key Takeaways
- Both TOVX and TVRD are clinical-stage biotechnology companies with no approved commercial products, making them high-risk, catalyst-driven equities.
- TOVX (Theriva Biologics) is advancing VCN-01, an oncolytic adenovirus, with recent positive clinical publications and non-dilutive licensing transactions.
- TVRD (Tvardi Therapeutics) is developing oral STAT3 inhibitors but has traded near 52-week lows amid a sustained downtrend and ongoing net losses.
- Relative performance favors TOVX, whose recent catalysts and analyst activity appear more constructive than TVRD's, which has declined roughly 77% over the past year.
- Tickeron AI Verdict: Based on trend consistency, catalyst flow, and relative positioning, Tickeron's AI currently favors TOVX over TVRD.
- For deeper context, explore TOVX Major News and TOVX Today's Price Move, as well as TVRD Major News and TVRD Today's Price Move.
- Interested in automated strategies? Explore the curated Trending AI Robots page to see which trading bots are currently best suited to market conditions.
Introduction
This stock comparison examines two small-cap, clinical-stage biotechnology companies that attract attention from traders seeking high-conviction, event-driven opportunities. Theriva Biologics (TOVX) and Tvardi Therapeutics (TVRD) both operate in oncology and inflammatory disease, yet they sit at very different points in their development cycles and market positioning. For investors and traders who follow clinical catalysts, relative performance, and sentiment shifts, understanding how these two names differ can clarify where momentum, risk, and opportunity currently sit. This comparison focuses on observable factors rather than speculation, offering a neutral view of each company's recent market behavior and strategic trajectory.
TOVX Overview and Recent Performance
Theriva Biologics (TOVX) is a diversified clinical-stage company developing therapeutics for cancer and related diseases of high unmet need. Its lead candidate, VCN-01, is an oncolytic adenovirus engineered to selectively replicate within tumor cells and degrade the tumor stroma (the structural barrier that shields tumors). In recent weeks, Theriva has reported several constructive developments, including the publication of Phase 2b VIRAGE trial results in metastatic pancreatic ductal adenocarcinoma (PDAC) in the peer-reviewed journal Nature Medicine. The company also announced the sale of its SYN-004 (ribaxamase) portfolio to Biossil Labs, receiving an upfront payment with the potential for up to $91 million in future regulatory and sales milestones plus royalties. These non-dilutive transactions and regulatory progress have supported analyst attention, including a Buy rating, even as the stock remains a low-priced, high-volatility micro-cap.
TVRD Overview and Recent Performance
Tvardi Therapeutics (TVRD) is a clinical-stage biopharmaceutical company focused on novel oral, small-molecule therapies that directly inhibit STAT3 (Signal Transducer and Activator of Transcription 3), a historically difficult-to-drug target linked to inflammatory and proliferative diseases. Its pipeline includes TTI-101, in Phase 1b/2 development for hepatocellular carcinoma (HCC) and fibrosis-driven conditions such as idiopathic pulmonary fibrosis (IPF), and TTI-109, a next-generation prodrug now in Phase 1. Recent market activity has been volatile: the company reported positive Phase 1 topline data for TTI-109, which triggered a sharp single-session rally, yet the shares have subsequently retraced toward 52-week lows amid a broader downtrend and sustained net losses. Analysts have nonetheless maintained largely Buy ratings, reflecting a wide divergence between short-term price action and longer-term clinical expectations.
Trending AI Robots
Tickeron maintains a large ecosystem of AI trading bots, with hundreds of automated strategies that collectively trade thousands of different tickers across varied styles, timeframes, and risk profiles. Because not every bot is suited to every market environment, Tickeron curates only the most relevant and best-performing strategies into its Trending AI Robots section. These featured bots differ in trading approach, holding period, performance statistics, and the specific sets of tickers they trade, allowing traders to review data such as historical win rates, trade counts, and profitability before selecting a strategy. The section is designed to surface strategies aligned with current conditions, offering a practical starting point for those who prefer systematic, data-driven approaches. Explore Trending AI Robots to evaluate which strategies currently rank among the most suitable.
Head-to-Head Comparison
The two companies share a clinical-stage profile but diverge in focus, momentum, and risk. TOVX is concentrated in oncology with an intravenously delivered oncolytic virus, while TVRD is built around oral STAT3 inhibitors spanning both cancer and fibrotic diseases. From a growth-driver standpoint, TOVX has recently monetized non-core assets to fund its lead program, whereas TVRD continues to rely primarily on its balance-sheet cash and equity financings. On recent momentum, TOVX has shown more constructive catalyst flow, including peer-reviewed publication and regulatory feedback, while TVRD has struggled against a persistent downtrend that has pushed it near 52-week lows. Risk factors are elevated for both given their micro-cap status and reliance on clinical milestones, but TVRD's steeper drawdown and lower price relative to analyst targets illustrate wider near-term uncertainty. Market sentiment, measured by analyst ratings, is broadly positive for both, yet the observable trend and stability currently differ materially.
Tickeron AI Verdict
Weighing trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would currently lean toward TOVX over TVRD. Theriva's recent peer-reviewed clinical publication, regulatory engagement, and non-dilutive licensing activity provide a steadier, more diversified catalyst backdrop, whereas Tvardi's shares remain under technical pressure near multi-month lows despite favorable analyst coverage. This is a probabilistic assessment based on observable factors rather than a definitive claim, and both names carry substantial downside risk given their pre-revenue status. Traders should view this verdict as one data point within a broader research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TOVX is a Hold and TVRD is a Hold.
Momentum Indicator for TOVX turns negative, indicating new downward trend
TOVX saw its Momentum Indicator move below the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 87 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TOVX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 48 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TOVX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TOVX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for TOVX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 65 of 75 cases where TOVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
TOVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.627) is normal, around the industry mean (3.498). P/E Ratio (0.116) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.753) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. TOVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TVRD in upward trend: price rose above 50-day moving average on November 09, 2026
TVRD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TVRD as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TVRD just turned positive on October 15, 2026. Looking at past instances where TVRD's MACD turned positive, the stock continued to rise in 27 of 38 cases over the following month. The odds of a continued upward trend are 71%.
Following a +64.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVRD advanced for three days, in 185 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TVRD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TVRD entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (3.498). P/E Ratio (-0.334) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. TVRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TVRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TOVX | TVRD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 96 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 83 | 61 | |
P/E GROWTH RATING 1..100 | 44 | 7 | |
SEASONALITY SCORE 1..100 | 50 | 47 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TOVX's Valuation (59) in the null industry is in the same range as TVRD (61). This means that TOVX’s stock grew similarly to TVRD’s over the last 12 months.
TOVX's Profit vs Risk Rating (100) in the null industry is in the same range as TVRD (100). This means that TOVX’s stock grew similarly to TVRD’s over the last 12 months.
TOVX's SMR Rating (99) in the null industry is in the same range as TVRD (99). This means that TOVX’s stock grew similarly to TVRD’s over the last 12 months.
TVRD's Price Growth Rating (61) in the null industry is in the same range as TOVX (83). This means that TVRD’s stock grew similarly to TOVX’s over the last 12 months.
TVRD's P/E Growth Rating (7) in the null industry is somewhat better than the same rating for TOVX (44). This means that TVRD’s stock grew somewhat faster than TOVX’s over the last 12 months.
| TOVX | TVRD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Advances ODDS (%) | N/A | 3 days ago 81% |
| Declines ODDS (%) | 2 days ago 90% | 13 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TOVX’s FA Score shows that 0 FA rating(s) are green while TVRD’s FA Score has 1 green FA rating(s).
- TOVX’s FA Score: 0 green, 5 red.
- TVRD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TOVX’s TA Score shows that 3 TA indicator(s) are bullish while TVRD’s TA Score has 4 bullish TA indicator(s).
- TOVX’s TA Score: 3 bullish, 5 bearish.
- TVRD’s TA Score: 4 bullish, 5 bearish.
Price Growth
TOVX (@Biotechnology) experienced а -15.27% price change this week, while TVRD (@Biotechnology) price change was +68.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
TOVX is expected to report earnings on Nov 11, 2026.
TVRD is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
TOVX and
Correlation & Price change
A.I.dvisor indicates that over the last year, TOVX has been loosely correlated with GOVX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if TOVX jumps, then GOVX could also see price increases.
| Ticker / NAME | Correlation To TOVX | 1D Price Change % | ||
|---|---|---|---|---|
| TOVX | 100% | -7.00% | ||
| GOVX - TOVX | 54% Loosely correlated | -22.03% | ||
| GNPX - TOVX | 50% Loosely correlated | +1.46% | ||
| VOR - TOVX | 42% Loosely correlated | -2.10% | ||
| TVRD - TOVX | 41% Loosely correlated | N/A | ||
| QNRX - TOVX | 40% Loosely correlated | -2.43% | ||
More | ||||
TVRD and
Correlation & Price change
A.I.dvisor indicates that over the last year, TVRD has been loosely correlated with TOVX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TVRD jumps, then TOVX could also see price increases.
| Ticker / NAME | Correlation To TVRD | 1D Price Change % | ||
|---|---|---|---|---|
| TVRD | 100% | N/A | ||
| TOVX - TVRD | 41% Loosely correlated | -7.00% | ||
| JSPR - TVRD | 27% Poorly correlated | -9.90% | ||
| NIKI - TVRD | 27% Poorly correlated | -8.00% | ||
| NRXP - TVRD | 27% Poorly correlated | -0.84% | ||
| VSTM - TVRD | 27% Poorly correlated | +0.34% | ||
More | ||||